The Gaithersburg-based firm, which has two manufacturing plants in Baltimore, is working on a human plasma-derived therapy for use in critically ill patients and people at high risk. The plasma is taken from blood donations of people who have recovered from the disease and have produced antibodies that can be used by the immune system to tackle invaders.